Cognios Beta Neutral Large Cap Fund LP bought a new stake in shares of Johnson & Johnson (NYSE:JNJ) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,678 shares of the company’s stock, valued at approximately $203,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. BlackRock Inc. boosted its position in shares of Johnson & Johnson by 4.7% in the first quarter. BlackRock Inc. now owns 175,389,024 shares of the company’s stock worth $22,476,102,000 after purchasing an additional 7,853,141 shares during the period. Massachusetts Financial Services Co. MA boosted its position in shares of Johnson & Johnson by 1.8% in the second quarter. Massachusetts Financial Services Co. MA now owns 30,303,272 shares of the company’s stock worth $3,676,999,000 after purchasing an additional 541,338 shares during the period. Fisher Asset Management LLC boosted its position in shares of Johnson & Johnson by 3.8% in the second quarter. Fisher Asset Management LLC now owns 13,118,604 shares of the company’s stock worth $1,591,811,000 after purchasing an additional 478,982 shares during the period. Sumitomo Mitsui Trust Holdings Inc. boosted its position in shares of Johnson & Johnson by 4.5% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 8,978,198 shares of the company’s stock worth $1,089,415,000 after purchasing an additional 387,504 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in shares of Johnson & Johnson by 9.5% in the first quarter. Dimensional Fund Advisors LP now owns 7,552,034 shares of the company’s stock worth $967,793,000 after purchasing an additional 654,350 shares during the period. Institutional investors own 66.06% of the company’s stock.

A number of research firms have weighed in on JNJ. Citigroup upped their price target on shares of Johnson & Johnson from $137.00 to $148.00 and gave the stock a “neutral” rating in a research report on Monday, October 22nd. Credit Suisse Group upped their price target on shares of Johnson & Johnson from $149.00 to $152.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 17th. Raymond James upped their price target on shares of Johnson & Johnson from $144.00 to $149.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 17th. Wells Fargo & Co reiterated an “outperform” rating and issued a $160.00 price target (up from $155.00) on shares of Johnson & Johnson in a research report on Wednesday, October 17th. Finally, HC Wainwright reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Wednesday, October 17th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the company’s stock. Johnson & Johnson has a consensus rating of “Hold” and a consensus target price of $142.54.

JNJ stock opened at $144.68 on Wednesday. Johnson & Johnson has a one year low of $118.62 and a one year high of $148.32. The company has a current ratio of 1.72, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $389.93 billion, a PE ratio of 19.82, a P/E/G ratio of 2.27 and a beta of 0.58.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 16th. The company reported $2.05 EPS for the quarter, topping the consensus estimate of $2.03 by $0.02. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.62%. The firm had revenue of $20.35 billion for the quarter, compared to the consensus estimate of $20.05 billion. During the same quarter in the previous year, the firm earned $1.90 earnings per share. The company’s quarterly revenue was up 3.6% compared to the same quarter last year. On average, equities research analysts predict that Johnson & Johnson will post 8.16 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 11th. Stockholders of record on Tuesday, November 27th will be issued a $0.90 dividend. This represents a $3.60 annualized dividend and a dividend yield of 2.49%. The ex-dividend date of this dividend is Monday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 49.32%.

In related news, CAO Ronald A. Kapusta sold 8,441 shares of the company’s stock in a transaction on Thursday, November 8th. The shares were sold at an average price of $145.15, for a total transaction of $1,225,211.15. Following the sale, the chief accounting officer now owns 17,284 shares of the company’s stock, valued at $2,508,772.60. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, COO Michael E. Sneed sold 29,000 shares of the company’s stock in a transaction on Monday, August 27th. The shares were sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the sale, the chief operating officer now directly owns 59,124 shares in the company, valued at approximately $7,969,915.20. The disclosure for this sale can be found here. Insiders sold 85,340 shares of company stock worth $11,992,396 in the last three months. Insiders own 0.22% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Cognios Beta Neutral Large Cap Fund LP Buys New Stake in Johnson & Johnson (JNJ)” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2018/11/14/cognios-beta-neutral-large-cap-fund-lp-buys-new-stake-in-johnson-johnson-jnj.html.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: What is a put option?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.